In Vitro Design of Preclinical Models for Chemotherapy Combinations in Human Breast Tumours

Journal Title: Journal of Clinical and Diagnostic Research - Year 2019, Vol 13, Issue 5

Abstract

ABSTRACT Introduction: Globally, breast cancer persists a main cause of mortality. Because the number of possible drug combinations is basically unlimited, a strategy for the design of combination chemotherapy regimen of two anti-breast cancer drugs and determining the most promising combinations is crucial for improving the therapeutic outcomes and overcome the multi-therapeutic approach and holds the promise of delivering therapy to those in need. Aim: To assess the activity of combination of Doxorubicin and 5-fluorouracil on Human Breast Cancer Cell line (MCF-7). Materials and Methods: The cytotoxicity of Doxorubicin (DOX) and 5 fluorouracil (5FU) drugs or their combinations were evaluated by using 3-(4,5-Dimethylthiazol-2-yl)-2, 5 Diphenyltetrazolium Bromide (MTT) viability assay against human breast cancer cell line MCF-7. Then, the combination effect proposed by Chou TC et al., based on IC50 values obtained from drugs alone and their combination was evaluated by Combination Index (CI) to determine the nature of synergism, antagonism and additivity action of drug combinations as: synergistic effect is recorded if CI <1, additive effect if CI=1, or antagonism if CI >1, the median-effect dose (Dm) also studied. Dose-Reduction Index (DRI) was also calculated to indicate the level of dose reduction for each drug in synergistic combination. Experiments were achieved with triplicate samples. The MTT assay data were expressed as mean±Standard Deviation (SD). The IC50 values for each drug were computed by GraphPad Prism 5.2 software (GraphPad Software Inc., USA). Dose-effect curve parameters, CI values, Fa-CI, DRI-Faplot were calculated by CompuSyn program. Results: The proliferation of MCF-7 cells was inhibited by 5 FU and DOX anti-cancer drugs in a dose-dependent effect. The DOX at (0.1) nM was antagonistic according to CI value which was 2.82283, while at (1) nM, the CI was 0.39429 that indicate strong synergistic action. Conclusion: This study confirmed the favourable effect of 5 FU in combination with DOX for treatment of breast cancer cell MCF-7 better than the single drug treatment.

Authors and Affiliations

Randa Mohammed Dhahi

Keywords

Related Articles

Trends in Septicaemic Patients Admitted in Tertiary Care Teaching Hospital in Andhra Pradesh, India

ABSTRACT Introduction: Septicaemia is one of the significant causes of morbidity and mortality in Intensive Care Units (ICUs). The rate of antimicrobial resistance in ICU is very high compared to general hospital setting...

Are Indian Peacekeepers on Path to Mental Peace?

ABSTRACT Introduction: There is paucity of literature on mental morbidity of United Nations (UN) peace keeping soldiers. Peacekeeping mission implies overseas deployment, hostile and harsh conditions, armed conflict and...

Cerebellar Cognitive Affective Syndrome-A Case Report

Abstract There are an increasing number of reports suggesting that cerebellum, apart from its significance in movement coordination, plays an important role in cognitive and emotional regulation. Cerebellar Cognitive Aff...

Unusual Severe Extra-Intestinal Manifestations of a Common Enteric Pathogen-Aeromonas Spp

Introduction: Aeromonas spp. are halophilic, Gram-negative bacilli. They are widely distributed in the soil and aquatic environment and have been associated with various extraintestinal infections, such as skin and soft-...

Intraosseous Neurofibroma of the Mandible: A Case Report and Review of Literature

Neurofibroma (NF) is a benign tumor of the peripheral nervous system. Head and neck NF are generally located in the soft tissue. The tumour is rarely seen intraosseously and most commonly such tumours are seen as solitar...

Download PDF file
  • EP ID EP585866
  • DOI 10.7860/JCDR/2019/40273.12859
  • Views 97
  • Downloads 0

How To Cite

Randa Mohammed Dhahi (2019). In Vitro Design of Preclinical Models for Chemotherapy Combinations in Human Breast Tumours. Journal of Clinical and Diagnostic Research, 13(5), 5-5. https://europub.co.uk./articles/-A-585866